156 related articles for article (PubMed ID: 15232793)
1. Calcium-enriched bread for treatment of uremic hyperphosphatemia.
Babarykin D; Adamsone I; Amerika D; Spudass A; Moisejev V; Berzina N; Michule L; Rozental R
J Ren Nutr; 2004 Jul; 14(3):149-56. PubMed ID: 15232793
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
[TBL] [Abstract][Full Text] [Related]
4. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
5. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
[TBL] [Abstract][Full Text] [Related]
6. Control of predialytic hyperphosphatemia by oral calcium acetate and calcium carbonate. Comparable efficacy for half the dose of elemental calcium given as acetate without lower incidence of hypercalcemia.
Morinière P; Djerad M; Boudailliez B; el Esper N; Boitte F; Westeel PF; Compagnon M; Brazier M; Achard JM; Fournier A
Nephron; 1992; 60(1):6-11. PubMed ID: 1738415
[TBL] [Abstract][Full Text] [Related]
7. Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial.
Wald R; Rabbat CG; Girard L; Garg AX; Tennankore K; Tyrwhitt J; Smyth A; Rathe-Skafel A; Gao P; Mazzetti A; Bosch J; Yan AT; Parfrey P; Manns BJ; Walsh M
Clin J Am Soc Nephrol; 2017 Jun; 12(6):965-973. PubMed ID: 28550080
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of calcium acetate-magnesium carbonate in the treatment of hyperphosphatemia in dialysis patients.
Helal I; Elkateb H; Hedri H; Hajri M; Hamida FB
Saudi J Kidney Dis Transpl; 2016; 27(6):1162-1167. PubMed ID: 27900961
[TBL] [Abstract][Full Text] [Related]
9. [The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].
Zwiech R; Dryja P; Łacina D; Króliczak V; Chrul S; Kacprzyk F
Wiad Lek; 2011; 64(1):9-14. PubMed ID: 21812357
[TBL] [Abstract][Full Text] [Related]
10. Comparison of calcium acetate with calcium carbonate as phosphate binder in patients on maintenance haemodialysis.
Saif I; Halim A; Altaf A; Saif M; Khalid M; Ahmad D; Imran H
J Ayub Med Coll Abbottabad; 2007; 19(4):26-8. PubMed ID: 18693591
[TBL] [Abstract][Full Text] [Related]
11. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
Joy MS; Finn WF;
Am J Kidney Dis; 2003 Jul; 42(1):96-107. PubMed ID: 12830461
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of calcium acetate and calcium carbonate for the control of predialysis hyperphosphatemia].
Djerad M; Morinière P; Westeel PF; el Esper N; Boitte F; Morsli R; Schenouda M; Compagnon M; Achard JM; Fournier A
Nephrologie; 1991; 12(4):193-7. PubMed ID: 1745337
[TBL] [Abstract][Full Text] [Related]
13. Improving diet recipe and cooking methods attenuates hyperphosphatemia in patients undergoing peritoneal dialysis.
Jiang N; Fang W; Gu AP; Yuan JZ; Yang XX; Lin AW; Ni ZH; Qian JQ
Nutr Metab Cardiovasc Dis; 2015 Sep; 25(9):846-852. PubMed ID: 26141941
[TBL] [Abstract][Full Text] [Related]
14. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease.
Chiang SS; Chen JB; Yang WC
Clin Nephrol; 2005 Jun; 63(6):461-70. PubMed ID: 15960148
[TBL] [Abstract][Full Text] [Related]
15. Serum ionized calcium, parathyroid hormone and phosphate in uremic patients during and between hemodialysis.
Rudnicki M; Frølich A; Haaber A; Tvedegaard E; Thode J
Clin Nephrol; 1993 Oct; 40(4):225-9. PubMed ID: 8261680
[TBL] [Abstract][Full Text] [Related]
16. Direct effect of the correction of acidosis on plasma parathyroid hormone concentrations, calcium and phosphate in hemodialysis patients: a prospective study.
Movilli E; Zani R; Carli O; Sangalli L; Pola A; Camerini C; Scolari F; Cancarini GC; Maiorca R
Nephron; 2001 Mar; 87(3):257-62. PubMed ID: 11287761
[TBL] [Abstract][Full Text] [Related]
17. Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia.
Mactier RA; Van Stone J; Cox A; Van Stone M; Twardowski Z
Clin Nephrol; 1987 Nov; 28(5):222-6. PubMed ID: 3427832
[TBL] [Abstract][Full Text] [Related]
18. Comparison between different dialysate calcium concentrations in nocturnal hemodialysis.
Toussaint ND; Polkinghorne KR; Kerr PG; Somerville CA; Agar JW
Hemodial Int; 2007 Apr; 11(2):217-24. PubMed ID: 17403174
[TBL] [Abstract][Full Text] [Related]
19. Calcium acetate used as phosphate binding treatment in uremic hyperphosphatemia.
Wikström B; Danielson BG; Fellström B
Adv Perit Dial; 1991; 7():221-4. PubMed ID: 1680430
[TBL] [Abstract][Full Text] [Related]
20. Use of alkaline calcium salts as phosphate binder in uremic patients.
Fournier A; Morinière P; Ben Hamida F; el Esjer N; Shenovda M; Ghazali A; Bouzernidj M; Achard JM; Westeel PF
Kidney Int Suppl; 1992 Oct; 38():S50-61. PubMed ID: 1405382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
